Get the Stockscreener App
1.195
2.14%
0.025
Pacific Biosciences Of California Inc stock is traded at $1.195, with a volume of 2.96M.
It is up +2.14% in the last 24 hours and down -8.08% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.17
Open:
$1.22
24h Volume:
2.96M
Relative Volume:
0.28
Market Cap:
$320.42M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-0.7967
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
-0.42%
1M Performance:
-8.08%
6M Performance:
-31.71%
1Y Performance:
-18.71%
1-Day Range:
$1.18
$1.25
1-Week Range:
$1.13
$1.25
52-Week Range:
$1.08
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.19 | 320.42M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
129.86 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.17 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
364.73 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
84.39 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.29 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Pacific Biosciences of California Selected by Davos Alzheimer's Collaborative as Technology Partner - marketscreener.com
PacBio partners with global Alzheimer’s initiative By Investing.com - Investing.com India
PacBio partners with global Alzheimer’s initiative - Investing.com Australia
PacBio (PACB) Joins DAC's North African Dementia Project | PACB Stock News - GuruFocus
PacBio Partners with Davos Alzheimer’s Collaborative to Advance Alzheimer's Research in North Africa - Nasdaq
Selling Pacific Biosciences of California Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - simplywall.st
Positive week for Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional investors who lost 57% over the past year - Yahoo
Pacific Biosciences of California jumps 22% after prelim Q1 results, guides FY - MSN
Canaccord maintains $3 price target on PACB, reiterates Buy By Investing.com - Investing.com South Africa
Tariffs, NIH ‘uncertainty’ force PacBio into layoffsSan Francisco Business Times - The Business Journals
Canaccord maintains $3 price target on PACB, reiterates Buy - Investing.com
PacBio outlines cost-cutting, revenue meets Q1 target By Investing.com - Investing.com South Africa
PacBio to cut jobs, lower spending over NIH funding cuts and tariffs - Reuters
Healthcare Stocks Ride a Tariffs-Relief Wave -- Healthcare Roundup - MarketScreener
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know - The Globe and Mail
Sequencing Company PacBio Cuts Costs Amid Uncertainty Around NIH Funding And New Tariffs - Benzinga
Simply Good Foods, Pacific Biosciences of California, Kura Sushi, Delta Air Lines And Other Big Stocks Moving Higher On Wednesday - Benzinga
Pacific Biosciences of California Sees Lower Q1 Revenue, Plans Job Cuts to Reduce Costs - MarketScreener
PacBio Q1 Prel. Revenue Down, Says Met Expectations; To Cut Jobs - Nasdaq
PacBio outlines cost-cutting, revenue meets Q1 target - Investing.com
Pacbio posts Preliminary Q1 2025 Revenue And Reiterates 2025 Revenue Guidance - marketscreener.com
Pacific Biosciences of California, Inc. Reiterates Earnings Guidance for the Full Year 2025 - marketscreener.com
PacBio's Bold Move: $50M Cost Cut Plan as Q1 Shows Record Consumables Growth - Stock Titan
PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million - Yahoo Finance
PacBio Strengthens Leadership: New CFO Joins with Strategic Equity Package - Stock Titan
Customer success story: The University of Bern takes long-read sequencing to the next level with SPRQ chemistry - PacBio
Pacific Biosciences of California appoints CFO - MSN
PACB stock touches 52-week low at $1.15 amid market challenges - Investing.com
PacBio names Jim Gibson as new CFO By Investing.com - Investing.com South Africa
Pacific Biosciences of California Names Jim Gibson CFO - Marketscreener.com
PacBio names Jim Gibson as new CFO - Investing.com
Jim Gibson To Join PacBio As Chief Financial Officer - MarketScreener
Jim Gibson to join PacBio as Chief Financial Officer - GlobeNewswire
Tech Giant CFO Who Raised $1B+ Joins PacBio: Ex-Tesla, Apple Executive to Drive Growth - Stock Titan
Publications March 2025 - Pacific Biosciences
Assessing Pacific Biosciences: Insights From 6 Financial Analysts - Benzinga
ATTENTION PACB SHAREHOLDERS: Investors Who Lost Money on Pacific Biosciences of California, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation - ACCESS Newswire
Here's Why You Should Retain PacBio Stock in Your Portfolio Now - MSN
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors - MSN
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - MSN
PacBio, Take2 Resolve DNA Sequencing Patent Infringement Dispute - Bloomberg Law News
Is Pacific Biosciences of California, Inc. (PACB) the Most Volatile Stock Under $3 For Day Trading? - Insider Monkey
10 Most Volatile Stocks Under $3 For Day Trading - Insider Monkey
Inspiring the next generation of scientists: How multidisciplinary science powers PacBio technology - Pacific Biosciences
Cantor Fitzgerald maintains PACB overweight rating, $2.50 target - Investing.com
Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks - The Globe and Mail
Pacific Biosciences of California Inc. (PACB) reports earnings - qz.com
Pacific Biosciences of California (PACB) Increases Yet Falls Behind Market: What Investors Need to Know - Yahoo Finance
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pacific Biosciences Of California Inc Stock (PACB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Van Oene Mark | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
6,486 |
9,126 |
1,497,695 |
| Farmer Michele | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
2,973 |
4,183 |
184,619 |
2.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):